Bank Of America Corp Graphite Bio, Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$2.24 - $2.66 $5,998 - $7,123	-2,678 Reduced 4.09%	62,753 $164,000
Q2 2023 Aug 14, 2023	SELL	$2.47 - $3.38 $25,969 - $35,537	-10,514 Reduced 13.84%	65,431 $170,000
Q1 2023 May 12, 2023	BUY	$1.85 - $3.21 $43,301 - $75,133	23,406 Added 44.55%	75,945 $186,000
Q4 2022 Feb 10, 2023	BUY	$2.82 - $3.59 $41,716 - $53,106	14,793 Added 39.19%	52,539 $174,000
Q3 2022 Nov 14, 2022	BUY	$2.82 - $4.24 $2,470 - $3,714	876 Added 2.38%	37,746 $120,000
Q2 2022 Aug 12, 2022	SELL	$2.14 - $5.23 $58,509 - $142,993	-27,341 Reduced 42.58%	36,870 $101,000
Q1 2022 May 16, 2022	SELL	$5.1 - $13.06 $10,602 - $27,151	-2,079 Reduced 3.14%	64,211 $328,000
Q4 2021 Feb 08, 2022	BUY	$8.41 - $16.71 $300,884 - $597,833	35,777 Added 117.25%	66,290 $824,000
Q3 2021 Nov 15, 2021	BUY	$15.81 - $28.39 $479,248 - $860,586	30,313 Added 15156.5%	30,513 $500,000
Q2 2021 Sep 13, 2021	BUY	$18.5 - $30.73 $3,700 - $6,146	200 New	200 $6,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.